We would love to hear your thoughts about our site and services, please take our survey here.
I felt that Peter Horby is very negative towards Synairgen. His tweet last week
https://twitter.com/PeterHorby/status/1354039490499780608?s=19
points to this. He could have easily been specific re the method of treatment for Interferon by decided on a very general
How do these findings fit with SOLIDARITY result of no benefit of interferon treatment in hospitalised COVID-19? Blocking of IFN a good or bad thing in severe disease?
He could have mentioned Interferon was Injected but didn't. I've got a pretty good BS detector and the attitude generally here from Peter Horby is just wrong. We're in a worldwide pandemic, he should be specific and not misleading and celebrate any findings that point to a potentially positive treatment option.
With the sad news about Sir Captain Tom getting Covid and articles like this, it's only a matter of time that press and media discussions turn to treatments and the governments complete lack of focus on them. Holgate has so much class and authority. He knows this works, he's more or less saying l, this is your last chance to show some proper support before you're made look like a bunch of buffoons.
He's in Luton Hospital where my brother in law passed away 2 weeks ago. Can't see this ending well. Luton didn't escalate treatment options for my Bother in Law because they said it wasn't safe to move him (reading between the lines it was really because ICU was full and his underlying health conditions meant they were giving him the best treatment they had available at the time which didn't include ICU.)
Sadly this really shines a light on the relative lack of effective Covid treatment options.
Spotted this on another forum, scary stuff coming out of Brazil. They're trying to work out why in the Amazonian city of Manaus, where antibodies had been previously estimated in 76 percent of the population, there has been a horrifying and deadly dramatic second wave, right in the middle of Brazilian summer in a place believed to have developed a quite robust community immune protection and perhaps true herd immunity.
In the first wave hospitals took 12 days to fill, this time around it took 24 hrs.
Worse case scenario is that this new strain has achieved near total immune escape.
Worth reading, no wonder the UK stopped people travelling from Brazil and the US jumped on supporting SNG001 so quickly https://nymag.com/intelligencer/amp/2021/01/brazils-new-covid-strain-raises-big-and-scary-questions.html
Perhaps we won't hear anything from NIH until the first patient has been dosed. That will kick start another round of PR and probably Handjob saying how wonderful Synairgen once they've realised the US Govt is giving huge support to #SNG001
Personally, I see them as the blockbuster video of testing and Covid has just hidden a fundamental flaw in their business model. BioTech driven change is coming which will, over time, have a huge impact on their market. They need to use their cash mountain carefully and acquire to offset that future risk.
Further to this, it was the trust's clinical director that gave the update and gave quite a lengthy overview of SNG001. It was mentioned that there were 10 hospitals on the trial and they're still trying to get on it and access SNG001 as a treatment. Sounded like a very positive update.
@Ghia I think there is a good chance we'll get emergency use authority whilst the Activ2 phase ll trial is ongoing once they take a first look at the data. They know they'll have existing phase 3 trial data to keep an eye on and so they'll be in a much safer position to grant EUA whilst the trials continue. Most of the recent EUA's were granted after interim data review so we don't need the trials to complete for authorisation to happen.
I'm pretty sure the Activ 2 trial isn't double blinded so they'll be providing data to a Data and Safety Monitoring Board for interim analyses.
Below is an existing activ 2 trial detail re masking
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Unblinded data will be provided to the Data and Safety Monitoring Board for interim analyses. Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation.
My wife works for a big regional NHS trust and attends a weekly virtual Covid update meeting. Today one of the Doctors on the virtual meet asked about whether the trust was enrolled as a trial centre for the latest inhaled interferon beta trial. The senior Covid consultant answered that unfortunately they were not but that the treatment looked very promising and they looked forward to hearing more about the trial outcome and the potential for having access to a new treatment.